Global brokerage Jefferies has issued 'Buy' ratings for HDFC AMC, Groww, and Emcure Pharmaceuticals, forecasting up to 18% upside. The report highlights earnings growth potential across all three, driven by market expansion and product innovation, though investors should track regulatory and competitive risks.
What Happened
Global investment firm Jefferies has released a positive outlook on three distinct Indian companies: HDFC Asset Management Company (HDFC AMC), Groww (Billionbrains Garage Ventures), and Emcure Pharmaceuticals. The brokerage has initiated or maintained 'Buy' ratings for all three, citing specific growth levers that could drive earnings expansion. Jefferies projects potential upside of approximately 18% from recent market valuations, basing its optimism on factors ranging from stable mutual fund flows to global product expansion and platform monetization.
HDFC AMC Outlook
Jefferies maintains a constructive view on HDFC AMC, setting a target price of ₹3,090. Despite a temporary slowdown in mutual fund inflows during May 2026—which the brokerage views as a normalization after record months—the outlook remains strong. The brokerage highlights that the company has effectively navigated Total Expense Ratio (TER) regulations, with distribution partners absorbing the impact. Strategic focus areas for the AMC include growth in Portfolio Management Services (PMS), Alternative Investment Funds (AIFs), and expansion in GIFT City. The firm anticipates a 21% compound annual growth rate in Assets Under Management (AUM) and 16% growth in operating profit over the next two fiscal years.
Groww's Ecosystem Strategy
Groww, which listed in late 2025, has received a 'Buy' rating with a target of ₹230. Jefferies points to the company's ecosystem strategy as a key growth driver. By expanding from basic equity broking into wealth management, mutual fund advisory, and overseas investment products, Groww aims to deepen its revenue per user. Initiatives such as 'Groww Prime' and the 'W by Groww' platform for affluent investors are seen as central to monetizing the existing user base. The brokerage believes Groww is well-positioned to capture the ongoing shift in Indian household savings from traditional yield-based products to equity-linked investments.
Emcure Pharmaceuticals Growth Levers
Emcure Pharmaceuticals, which has seen stock price momentum recently, carries a 'Buy' rating with a target of ₹2,100. Jefferies highlights a mid-teen revenue growth expectation for FY27, supported by a healthy product pipeline. The company’s strategy involves diversifying through in-licensing agreements, expanding into dermatology and consumer healthcare in India, and leveraging its presence in European and Canadian markets. The brokerage projects a 20% earnings compound annual growth rate between FY26 and FY29, driven by specialty product launches.
Risks To Consider
While the brokerage remains optimistic, investors should consider sector-specific risks. For HDFC AMC, competition in the mutual fund space and potential regulatory tweaks to commission structures could influence margins. For Groww, being a pure-play digital broker means the business is sensitive to market volatility and changes in trading activity; intense competition in the fintech space also remains a factor. Emcure Pharmaceuticals faces the standard risks associated with the pharmaceutical sector, including pricing pressure in the US, regulatory scrutiny, and the successful execution of its global pipeline of specialty drugs.
What Investors Should Track
Investors monitoring these companies should track key performance indicators such as SIP retention rates for HDFC AMC, user monetization trends for Groww, and the pace of new product approvals for Emcure Pharmaceuticals. Additionally, management commentary on future quarterly results will be critical to verify if the growth targets laid out by the brokerage align with actual operational execution.